JP7629007B2 - 置換二環ヘテロアリール化合物 - Google Patents

置換二環ヘテロアリール化合物 Download PDF

Info

Publication number
JP7629007B2
JP7629007B2 JP2022520195A JP2022520195A JP7629007B2 JP 7629007 B2 JP7629007 B2 JP 7629007B2 JP 2022520195 A JP2022520195 A JP 2022520195A JP 2022520195 A JP2022520195 A JP 2022520195A JP 7629007 B2 JP7629007 B2 JP 7629007B2
Authority
JP
Japan
Prior art keywords
pyrrolo
isopropyl
pyridin
triazolo
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022520195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550203A5 (https=
JP2022550203A (ja
JPWO2021067326A5 (https=
Inventor
ラトナ クマール，スリーカンタ
パスヌーリ，ラクスマン
ヘッジ，スブラマニア
レディ，アヌパマ カンディ ラマチャンドラ
ブチ ラジュ バレ，ドゥルガ
ジェイ ディックマン，アラリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2022550203A publication Critical patent/JP2022550203A/ja
Publication of JP2022550203A5 publication Critical patent/JP2022550203A5/ja
Publication of JPWO2021067326A5 publication Critical patent/JPWO2021067326A5/ja
Application granted granted Critical
Publication of JP7629007B2 publication Critical patent/JP7629007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022520195A 2019-10-01 2020-09-30 置換二環ヘテロアリール化合物 Active JP7629007B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908840P 2019-10-01 2019-10-01
US62/908,840 2019-10-01
PCT/US2020/053358 WO2021067326A1 (en) 2019-10-01 2020-09-30 Substituted bicyclic heteroaryl compounds

Publications (4)

Publication Number Publication Date
JP2022550203A JP2022550203A (ja) 2022-11-30
JP2022550203A5 JP2022550203A5 (https=) 2023-09-28
JPWO2021067326A5 JPWO2021067326A5 (https=) 2023-09-28
JP7629007B2 true JP7629007B2 (ja) 2025-02-12

Family

ID=72896115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520195A Active JP7629007B2 (ja) 2019-10-01 2020-09-30 置換二環ヘテロアリール化合物

Country Status (6)

Country Link
US (1) US12448395B2 (https=)
EP (1) EP4041730A1 (https=)
JP (1) JP7629007B2 (https=)
KR (1) KR20220075381A (https=)
CN (1) CN114761404B (https=)
WO (1) WO2021067326A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116783202A (zh) * 2021-02-09 2023-09-19 吉利德科学公司 噻吩并吡咯化合物
PL4291562T3 (pl) * 2021-02-09 2026-02-16 Gilead Sciences, Inc. Związki tienopirolu
CR20230478A (es) 2021-04-16 2023-11-30 Gilead Sciences Inc Compuestos de tienopirrol.
KR20240056747A (ko) * 2021-09-10 2024-04-30 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
WO2026002036A1 (zh) * 2024-06-26 2026-01-02 北京双鹤润创科技有限公司 一种化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019125977A1 (en) 2017-12-18 2019-06-27 Bristol-Myers Squibb Company 4-azaindole compounds
WO2019126253A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2000035886A2 (en) 1998-12-18 2000-06-22 Axys Pharmaceuticals, Inc. (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
HRP20020349A2 (en) 1999-10-19 2004-02-29 Merck & Co Inc Tyrosine kinase inhibitors
AU2003235741B8 (en) 2002-01-07 2009-01-15 Eisai R&D Management Co., Ltd. Deazapurines and uses thereof
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
BRPI0411514A (pt) 2003-06-20 2006-08-01 Coley Pharm Gmbh antagonistas de receptor toll-like de molécula pequena
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
RS50821B (sr) 2005-06-27 2010-08-31 Sanofi-Aventis Derivati pirazolopiridina kao inhibitori beta-adrenergičnog receptora kinaze 1
CA2648652A1 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
JP2010511018A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
WO2010036905A1 (en) 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Benzoxazole compounds and methods of use
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JP5864417B2 (ja) 2009-07-16 2016-02-17 マリンクロッド エルエルシー トール様受容体９のアンタゴニストとしての（＋）−モルフィナンおよびその治療的使用
RU2012116207A (ru) 2009-09-24 2013-10-27 Ф.Хоффманн-Ля Рош Аг Производные индола в качестве модуляторов crac
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
DE102009058280A1 (de) 2009-12-14 2011-06-16 Merck Patent Gmbh Thiazolderivate
WO2012054862A2 (en) 2010-10-21 2012-04-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritis and related skin conditions
DK2663550T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
CN103562201B (zh) 2011-01-12 2016-10-19 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
KR102052215B1 (ko) 2011-06-01 2019-12-04 야누스 바이오테라퓨틱스, 인크. 신규한 면역 시스템 조절제
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
KR101913135B1 (ko) 2011-07-15 2018-10-30 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체
WO2013052550A2 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
TWI619704B (zh) 2012-05-18 2018-04-01 大日本住友製藥股份有限公司 羧酸化合物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US9761813B2 (en) 2012-08-10 2017-09-12 Doosan Corporation Organic light-emitting compound and organic electroluminescent device using same
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
JP6223563B2 (ja) 2013-10-14 2017-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
CN105992766A (zh) 2013-12-13 2016-10-05 武田药品工业株式会社 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物
HUE054672T2 (hu) 2014-08-15 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
EP3398948A3 (en) 2014-08-22 2018-12-05 Janus Biotherapeutics, Inc. 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
MX2018014034A (es) 2016-05-25 2019-08-29 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
BR112019001270A2 (pt) 2016-07-30 2019-04-30 Bristol-Myers Squibb Company compostos indol substituídos com dimetoxifenila como inibidores de tlr7, tlr8 ou tlr9
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
CN120699039A (zh) * 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
MX2022005359A (es) * 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
MX2023002248A (es) * 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2023003060A (es) * 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019125977A1 (en) 2017-12-18 2019-06-27 Bristol-Myers Squibb Company 4-azaindole compounds
WO2019126253A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
野崎正勝 等，創薬化学，第１版，株式会社化学同人，1995年，pp.98-99

Also Published As

Publication number Publication date
US20240124489A1 (en) 2024-04-18
WO2021067326A1 (en) 2021-04-08
CN114761404A (zh) 2022-07-15
JP2022550203A (ja) 2022-11-30
CN114761404B (zh) 2025-02-21
KR20220075381A (ko) 2022-06-08
EP4041730A1 (en) 2022-08-17
US12448395B2 (en) 2025-10-21

Similar Documents

Publication Publication Date Title
JP7629007B2 (ja) 置換二環ヘテロアリール化合物
CN104470925B (zh) 作为激酶抑制剂的咪唑并三嗪甲腈
CN110105346B (zh) 选择性取代的喹啉化合物
TWI719949B (zh) 稠合五環咪唑衍生物
CN111699185A (zh) 6-氮杂吲哚化合物
CN102548557B (zh) 用于降低β-淀粉状蛋白生成的化合物
CN111819176A (zh) 4-氮杂吲哚化合物
CN102918042B (zh) 8-甲基-1-苯基-咪唑[1,5-a]吡嗪化合物
JP7652772B2 (ja) 置換ピラゾール化合物
CN111448190A (zh) 取代的吲哚化合物
CN112166110A (zh) Shp2磷酸酶抑制剂及其使用方法
CN111511744A (zh) 二氮杂吲哚化合物
CN111491930A (zh) 可用作tlr抑制剂的经取代的吲哚化合物
CN110088096A (zh) 作为泛素特异性蛋白酶7的抑制剂的哌啶衍生物
CN105530932A (zh) 作为bik抑制剂的伯甲酰胺
TW201713657A (zh) 作為抗癌劑之三環化合物
CN112955450A (zh) 经取代的吲哚和吲唑化合物
WO2024125532A1 (zh) 作为CDKs抑制剂的新型并杂环类新化合物及其应用
TW201202247A (en) A new 4, 5-fused pyrimidine derivate
KR102904576B1 (ko) 치환된 벤즈이미다졸론 화합물
CN110049979A (zh) 布罗莫结构域抑制剂
WO2023217201A2 (zh) 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
US20230139171A1 (en) System and method for instructing one or more weather drones
HK40094579A (zh) 作为iap拮抗剂的三环杂环化合物
HK40097443A (zh) 作为ent抑制剂用於治疗癌症的大环二胺衍生物以及其与腺苷受体拮抗剂的组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240905

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250130

R150 Certificate of patent or registration of utility model

Ref document number: 7629007

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150